Collaborative investment to counter drug resistance
GARDP’s mission is to discover, develop, and deliver new antibiotic treatment options for drug-resistant infections that pose the greatest threat to health. This work could not be done without investment and support from our funding partners, each of whom understand the urgent need to address drug resistance. We would like to thank all of them.
We would also like to acknowledge the ongoing recognition that the G7 and G20 give to AMR as a crucial global health issue.
In 2021, the Swiss government recognized our mission to develop new treatments for drug-resistant infections by granting a privileged status to GARDP.
2021 partnership and funding milestones
January
Signed a Memorandum of Understanding (MOU) with the British Society for Antimicrobial Chemotherapy (BSAC) to collaborate on education, policy, and advocacy around antibiotic resistance.
February
The UK government announced £1.5 million of additional funding for GARDP to support the ongoing development of zoliflodacin, a potential new treatment for gonorrhoea.
March
The Swiss government recognized our mission to develop new treatments for drug-resistant infections by granting a privileged status to GARDP.
April
Signed a Declaration of Intent with the French Ministry for Europe and Foreign Affairs to explore opportunities for collaboration and strengthening activities to tackle antibiotic resistance.
May
Signed an MOU with the Indian Council of Medical Research (ICMR) to explore joint opportunities to tackle antibiotic resistance in India and globally.
The South African Medical Research Council renewed its funding to GARDP, providing an additional 4 million South African rand (ZAR) to support our activities in developing new and improved antibiotic treatments for drug-resistant infections.
June
The Japanese and British governments separately announced investments of ¥200 million and £1 million, respectively, in GARDP to support our work in tackling drug-resistant infections.
July
Signed an MOU with the Clinton Health Access Initiative (CHAI) and Shionogi & Co., Ltd to accelerate access to cefiderocol for bacterial infections in patients with limited treatment options, including in low- and middle-income countries (LMICs).
Initiated a partnership with German pharmaceutical company InfectoPharm to develop improved treatment options for neonatal sepsis using combinations of existing antibiotics.
September
Signed an MOU with the Department of Disease Control of the Thailand Ministry of Public Health (Thai DDC) to collaborate on an access and stewardship plan for zoliflodacin.
The Republic and Canton of Geneva announced funding of CHF 540,000 to support the development of zoliflodacin.
Partners Around the Globe
Partnerships with governments, academia, research centres, and industry are at the heart of GARDP’s work. Without the support of its partners, GARDP’s achievements to date would not have been possible.
GARDP is also collaborating with research centres on activities in the following countries: Bangladesh, Brazil, China, Greece, India, Italy, Kenya, the Netherlands, South Africa, Thailand, Vietnam, Uganda, and the United States.
